|
IMP321 IND Allowance in Pancreatic Cancer
Immutep S.A. announced today that the FDA, after review of the Investigational New Drug Application (IND), has allowed the administration of IMP321 in cancer patients in a Phase I trial conducted by Dr. William G. Hawkins at the Washington University School of Medicine in Saint Louis (MO).Published 10/2008 by admin@immutep.com © 2002 Immutep, S.A.
|
Press Release
04/2012 - Immutep and Lonza Sign Agreement for Cell Line Selection, Cell Banking and Process Development of ImmuFact® IMP321
Immutep and Lonza announced today an agreement for cell line ...
02/2012 - Interview Frederic Triebel with PharmaTelevision 
Get the Flash ...
01/2011 - Immutep and GlaxoSmithKline sign licence agreement for IMP731, a novel therapeutic antibody for the treatment of autoimmune diseases 
Immutep S.A. announced today the execution of a licence agreement ...
09/2010 - Immutep announces final results in phase I/II chemoimmunotherapy trial in metastatic breast cancer. 
Clinical research paper describes IMP321’s potency in achieving ...
05/2010 - Immutep Announces Oral Presentation at ASCO Annual Meeting of IMP321 Final Results In Phase I/II Chemoimmunotherapy Trial 
Immutep S.A. announced today that the final results from its Phase ...
|
|||||||
